ESR1 and neoplasm: We developed a two‐component prognostic model for endocrine therapy response using the tumor transcriptomes and long‐term survival outcomes of 833 ER+/HER2− tumors that received endocrine therapy (Curtis et al, 2012; Pereira et al, 2016; Table 1, Fig 1A).